CollabRx, Inc. Launches Commercial Service for the Interpretation of Clinical Cancer Sequencing
8/8/2013 10:00:28 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN FRANCISCO, Aug. 8, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, today announced the launch of the company's Genetic Variant Annotation™ (GVA™) service. The GVA service is a new product and the company's first offering for the clinical laboratory market. CollabRx will provide the GVA service to the molecular diagnostic segment of the clinical laboratory market which includes reference laboratories, hospital laboratories, research institutions, and laboratories within academic medical centers.
Help employers find you! Check out all the jobs and post your resume.
comments powered by